6976 results for
Refine Your Search
Enhancing Connection and Communication with Community-Based Oncology Practices to Improve Cancer Clinical Trial Recruitment: The ECCO Study
In collaboration with 10 community-based oncology practice sites, this study will implement a multi-level intervention trial to test the effectiveness…
Epigenetic heterogeneity in age-related clonal hematopoiesis and acute myeloid leukemia
Our focus is to unravel how clonal hematopoiesis (CH) progresses to leukemia. We will investigate how epigenetic heterogeneity affects Tet2-mutant hem…
A randomized clinical trial of oral vitamin A to reduce chronic graft versus host disease in BMT
Vitamin A is safe, well tolerated and positively affects gut immune health. Graft versus host disease (GVHD) is a life-threatening complication of bon…
Patient-Reported Outcomes and Survivorship in Histiocytic Neoplasms
Advances in the treatment of Langerhans cell histiocytosis and Erdheim-Chester disease have led to a growing survivor population; however, there is a …
Novel Immunotherapy Combinations in Relapsed, Refractory Mantle Cell Lymphoma
We are evaluating two parallel clinical trials with synergistic immunotherapies in mantle cell lymphoma (MCL), including 1) tafasitamab and lenalidomi…
Targeting SF3B1 splicing factor mutant myeloid malignancies through dependency on GPATCH8
Mutations in RNA splicing factors, particularly those involving the core splicing factor SF3B1 are amongst the most common mutations found in myeloid …
Improving outcomes with immune therapies for multiple myeloma
The primary focus of research is to better understand mechanisms of resistance to immunotherapies and design treatment approaches to improve outcomes.…
Novel targeted therapies for acute myeloid leukaemia and multiple myeloma
Outcomes for acute myeloid leukemia (AML) and multiple myeloma (MM) patients remain inadequate and new treatment options to combat resistance against …
Multiple Myeloma Support from the Microenvironment: Bone Marrow Adipocytes and the Fatty Acid Binding Proteins
Our project’s goal is to change how multiple myeloma is understood and treated by interrogating a novel part of the cellular “soil” (the bone marrow a…
Bispecific antibody-based frontline therapy for follicular lymphoma
We are conducting a clinical trial testing a novel form of immunotherapy, called a bispecific antibody, as part of initial treatment for patients with…
Targeting mutant IDH2 in angioimmunoblastic T-cell lymphoma
Angioimmunoblastic T-cell lymphoma is a rare, aggressive form of T-cell lymphoma associated with poor clinical outcomes in response to current therape…
Zachary Epstein-Peterson
I am a clinical-translational researcher focusing on new treatments for lymphomas with a particular focus on T-cell/cutaneous lymphomas. Since enterin…
MULTIlayer Predictive models for relapsed MCL after ibrutinib as first line therapY (MULTIPLY)
The MULTIPLY is a large multi-institutional project aimed at characterization of a variety of clinical predictors, both baseline and at relapse throug…
Martin Dreyling
Martin Dreyling is Professor of Medicine and head of the lymphoma programme at the Department of Medicine III, LMU Hospital Munich. He studied at the …
Identifying the oncogenic cooperation between IRF4 and MYD88l265p and their impact on the Tumor Microenvironment of Waldenstrom Macroglobulinemia
Although many patients with IgM MGUS remain asymptomatic, some of them progress to Waldenstrom Macroglobulinemia (WM) requiring treatment. Recently, w…
Limited-duration bispecific antibody therapy for multiple myeloma
Bispecific antibodies are a new, highly effective immunotherapy for multiple myeloma. Most bispecific antibody therapies have been tested as continuou…
Prevention of antigen escape by modulation of off-target tumor killing in T cells
T-cell mediated therapies are all impeded by the same cause- tumoral antigen (Ag) escape: rare Ag– cells in tumors survive the initial attack and lead…
Understanding How Hematopoietic Developmental State Determines Oncogenic KMT2A Fusion Formation and Leukemic Potential
My goal is to understand how cancer-associated gene fusions arise and cause disease. Specifically, I am studying how oncogenic fusions involving the g…
Shazia Nakhoda
Dr. Nakhoda is a clinician-scientist in the department of hematology/oncology at Fox Chase Cancer Center. She serves as steering committee member for …
Role of ID2 in mature T-cell lymphoma
Overexpression of ID2 is a recurrent event in mature T-cell lymphoma (TCL), and its significance is yet to be established. We will use a multidiscipli…
RECONNECT: Overcoming Racial and Ethnic Inequity in Clinical Trial Enrollment via Clinical Trial Nurse Navigation and Provider Communication Training
This study will implement a skill-based didactic course for providers to improve the quality of communication around structural racism, mistrust, impl…
Addressing Inequities in Access to Care for Patients with Hematologic Malignancy: Understanding the Impact of Telehealth Policies in Medicaid
Telehealth could improve access for Medicaid patients with a blood cancer who experience barriers to specialty care, but not all specialists offer it.…
Anushree Vichare
Dr. Vichare’s research investigates the impact of health policies on health equity. Her training as primary care physician and health services researc…